Description
Description
This page contains brief details about the drug olaparib, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.
| LYNPARZA TAB 150 MG BL | 56 TAB | 257300 | 306327 |
| LYNPARZA TAB 100 MG BL | 56 TAB | 242638 | 303296 |
Date of Approval
Olaparib is an anticancer medicine referred to as the Poly Adenosine Diphosphate-Ribose Polymerase (PARP) inhibitor. It was approved for its medical use on 19th December 2014.
Mechanism of Action of Olaparib
Olaparib Tablet is a biological agent that acts as targeted drug therapy in cancer treatment. It is classified as a PARP inhibitor. PARP enzymes facilitate multiple DNA repair pathways and these repair mechanisms lead to the development of cancer cells. These enzymes specifically target cells with mutations in BRCA genes. Olaparib works by inhibiting PARP enzymes blocks repair of single stranded DNA, and ultimately hinders the growth and development of cancer cells. Olaparib is prescribed alone or in combination with other anticancer drugs like bevacizumab.
Uses of Olaparib
Olaparib Tablet has been developed as a maintenance therapy to treat adult patients with cancer in the ovaries, fallopian tube, peritoneum, pancreas, prostate due to BRCA mutation and have completely or partially responded to platinum-based chemotherapy.
Olaparib Dosage available
The recommended dose of Olaparib Tablet is 300mg twice a day with or without food. Olaparib Tablet is available in the doses of 100mg and 150mg and the strength varies according to the patient’s health condition. In patients with kidney impairment, the recommended dose is 200mg twice a day.
